The GenCRISPR™ Ultra Cas9 product line provides customers with a selection of research use, basic GMP and GMP compliant Cas9 nucleases. The Cas9 protein can be formed with the guide RNA into a ribonucleoprotien (RNP) complex. The use of an RNP complex to perform gene editing has been shown to reduce the challenges encountered with other CRISPR gene editing techniques such as viral and plasmid delivery. Challenges include off-target effects, cell viability and trascprition/translational challenges.
GenCRISPR™ Ultra NLS-Cas9-basic GMP is produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with an N-terminal nuclear localization signal (NLS).
GenScript’s basic GMP products retain the key hallmarks of GMP manufacturing while reducing costs and shortening development timelines. It is a faster and more cost-effective alternative to GMP products. We can provide the documents support for your IND filing. The basic GMP also makes it easy for moving to a GMP product as you progress toward commercialization.